Table 3. Enzyme-inhibitory complexes in HAE-C1INH patients and healthy controls after activation with ellagic acid.

	FXIIa-C1INH (A.U.)	Kallikrein-C1INH (A.U.)	FXIa-C1INH (A.U.)	FXIa-AT (A.U.)
	median [IQR]	median [IQR]	median [IQR]	median [IQR]
No addition of C1-esterase inhibitor
Healthy controls (n = 10)	137.2 [122.6-162.7]	80.0 [74.1-93.1]	84.1 [73.1-97.3]	91.3 [80.3-102.2]
HAE-C1INH remission (n = 17)	45.9 [22.8-59.0]*	38.7 [24.6-48.9]*	14.3 [9.9-29.8]*	134.5 [118.4-163.5]*
HAE-C1INH attack (n = 10)	25.5 [13.3-43.6]*	24.1 [11.1-31.3]*	9.2 1.30-11.0]*	121.6 [89.1-135.6]
Addition of C1-esterase inhibitor
Healthy controls (n = 10)	114.7 [104.6-132.4]	69.7 [60.3-76.3]	109.2 [97.9-123.5]	88.6 [80.0-95.0]
HAE-C1INH remission (n = 16)	77.10 [67.6-86.6]* #	32.3 [25.7-42.9]*	63.8 [44.4-98.1]* #	126.6 [110.3-160.6]*
HAE-C1INH attack (n = 7)	65.7 [40.7-89.0]* #	17.9 [0.6-36.5]*	32.2 [17.9-50.5]* #	107.8 [100.0-115.1]

C1INH: C1 esterase inhibitor; HAE: hereditary angioedema, IQR: interquartile range; A.U: arbitrary units

* Significant increase or decrease in level of inhibitory complexes compared to healthy controls (p < 0.05)

# Significant increase in inhibitory complexes compared to no addition of C1 esterase inhibitor (p < 0.05)